The ALIAS Pilot Trial
- 1 August 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 37 (8), 2100-2106
- https://doi.org/10.1161/01.str.0000231388.72646.05
Abstract
Background and Purpose— In preclinical stroke models, high-dose human albumin confers robust neuroprotection. We investigated the safety and tolerability of this therapy in patients with acute ischemic stroke. Methods— The ALIAS ( Al bumin i n A cute S troke) Pilot Clinical Trial used a multiple-tier, open-label, dose-escalation design. Subjects with acute ischemic stroke (NIH Stroke Scale [NIHSS] of 6 or above) received a 2-hour infusion of 25% human albumin (ALB) beginning within 16 hours of stroke onset. Six successive ALB dose tiers were assessed ranging from 0.34 to 2.05 g/kg. Neurologic and cardiac function was sequentially monitored. At 3 months, the NIHSS, modified Rankin Scale, and Barthel Index were measured. Results— Eighty-two subjects (mean age, 65 years) received ALB at 7.8±3.4 hours after stroke onset (mean±standard deviation). Forty-two patients also received standard-of-care intravenous tissue plasminogen activator (tPA). Vital signs were unaltered by ALB treatment. Dose-related increases in plasma albumin and mild hemodilution were maximal at 4 to 12 hours. Age-related plasma brain natriuretic peptide levels increased at 24 hours after ALB but did not predict cardiac adverse events. The sole ALB-related adverse event was mild or moderate pulmonary edema in 13.4% of subjects, which was readily managed with diuretics. In the tPA-treated subgroup, symptomatic intracranial hemorrhage occurred in only one of 42 subjects. Conclusions— Twenty-five percent human albumin in doses ranging up to 2.05 g/kg was tolerated by patients with acute ischemic stroke without major dose-limiting complications. tPA therapy did not affect the safety profile of ALB. The companion article presents neurologic outcome data and efficacy analysis in these subjects.This publication has 11 references indexed in Scilit:
- Neuroprotection for ischemic stroke: Two decades of success and failureNeuroRX, 2004
- Delayed post-ischemic albumin treatment neither improves nor worsens the outcome of transient focal cerebral ischemia in ratsBrain Research, 2003
- Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albuminJournal of Neurochemistry, 2002
- Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studiesEuropean Journal of Pharmacology, 2001
- Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapyThe Lancet, 2000
- Pathobiology of ischaemic stroke: an integrated viewTrends in Neurosciences, 1999
- Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in ratsJournal of Neurosurgery, 1997
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- REVIEW ■ : Neuroprotection in Brain Ischemia: An Update (Part IThe Neuroscientist, 1995
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993